Related Experiment Videos
Suspected beta-antagonist-induced thrombocytopenia
Pamela L Stamm1, J Kimble Jenkins, Howard G Vigrass
1Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, 125 Walker Boulevard, Auburn, AL 36849-0001, USA. stammpl@auburn.edu
The Annals of Pharmacotherapy
|February 11, 2005
Summary
This case report suggests beta-antagonist medications may cause thrombocytopenia (low platelet count). Discontinuing nadolol rapidly improved platelet levels, indicating a possible drug-induced adverse effect.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Background:
- Thrombocytopenia is a condition characterized by abnormally low levels of platelets.
- Beta-antagonists are commonly prescribed medications for cardiovascular conditions.
- Drug-induced thrombocytopenia is a potential adverse effect of various medications.
Observation:
- A patient with systemic lupus erythematosus developed recurrent thrombocytopenia.
- Splenectomy did not resolve the thrombocytopenia, suggesting a non-sequestration cause.
- Platelet counts significantly improved within 24 hours of discontinuing nadolol.
Findings:
- The temporal relationship between nadolol administration and thrombocytopenia, along with rapid platelet recovery upon withdrawal, strongly suggests nadolol-induced thrombocytopenia.
- The Naranjo probability scale indicated a possible causal link between beta-antagonist use and the adverse event.
- This case adds to the limited literature on beta-antagonist-associated thrombocytopenia.
Implications:
- Clinicians should consider beta-antagonists, specifically nadolol, as a potential cause of thrombocytopenia in patients with unexplained low platelet counts.
- Discontinuation of the suspected beta-antagonist may lead to rapid resolution of thrombocytopenia.
- Further investigation into the mechanisms of beta-antagonist-induced thrombocytopenia is warranted.